Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

Baker Capital Strategies

Free Registration

Register for access to news, tools, alerts and reports.

THEMA Basic included at launch.

Use at least 8 characters.

BCS
Home/The Filing Wire/Kazia Therapeutics Limited/ADR/ 424B3

SEC Filing · 424B3

Kazia Therapeutics Limited/ADR

SEC Filing

Filed Oct 16, 2024Accepted Oct 16, 2024, 11:10 AM EDTCIK 1055886Accession 0001019155-24-000296
View company →Permanent SEC source ↗
Share

Recent company filings

  1. EFFECT filingSep 25, 2026
  2. F-6 filingSep 18, 2026
  3. 424B3 filingApr 4, 2025
  4. 424B3 filingOct 16, 2024
  5. 424B3 filingOct 16, 2024

As-filed source

Primary evidence
As filedOpen full document ↗

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.